<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25855976</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease.</ArticleTitle><Pagination><StartPage>e0003692</StartPage><MedlinePgn>e0003692</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003692</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0003692</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) and coxsackieviruses (CV) are the major causative agents of hand, foot and mouth disease (HFMD). There is not currently a vaccine available against HFMD, even though a newly developed formalin-inactivated EV71 (FI-EV71) vaccine has been tested in clinical trial and has shown efficacy against EV71. We have designed and genetically engineered a recombinant adenovirus Ad-EVVLP with the EV71 P1 and 3CD genes inserted into the E1/E3-deleted adenoviral genome. Ad-EVVLP were produced in HEK-293A cells. In addition to Ad-EVVLP particles, virus-like particles (VLPs) formed from the physical association of EV71 capsid proteins, VP0, VP1, and VP3 expressed from P1 gene products. They were digested by 3CD protease and confirmed to be produced by Ad-EVVLP-producing cells, as determined using transmission electron microscopy and western blotting. Mouse immunogenicity studies showed that Ad-EVVLP-immunized antisera neutralized the EV71 B4 and C2 genotypes. Activation of VLP-specific CD4+ and CD8+/IFN-&#x3b3; T cells associated with Th1/Th2-balanced IFN-&#x263;, IL-17, IL-4, and IL-13 was induced; in contrast, FI-EV71 induced only Th2-mediated neutralizing antibody against EV71 and low VLP-specific CD4+ and CD8+ T cell responses. The antiviral immunity against EV71 was clearly demonstrated in mice vaccinated with Ad-EVVLP in a hSCARB2 transgenic (hSCARB2-Tg) mouse challenge model. Ad-EVVLP-vaccinated mice were 100% protected and demonstrated reduced viral load in both the CNS and muscle tissues. Ad-EVVLP successfully induced anti-CVA16 immunities. Although antisera had no neutralizing activity against CVA16, the 3C-specific CD4+ and CD8+/IFN-&#x3b3; T cells were identified, which could mediate protection against CVA16 challenge. FI-EV71 did not induce 3C-mediated immunity and had no efficacy against the CVA16 challenge. These results suggest that Ad-EVVLP can enhance neutralizing antibody and protective cellular immune responses to prevent EV71 infection and cellular immune responses against CV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsou</LastName><ForeName>Yueh-Liang</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan; Graduate Program of Biotechnology in Medicine, Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Hsiao-Yun</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan; Graduate Program of Biotechnology in Medicine, Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shu-Ling</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shang-Rung</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Institute of Oral Medicine, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hsiao-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chieh</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Taiwan; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508717">IL17A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018793">Interleukin-13</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018793" MajorTopicYN="N">Interleukin-13</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25855976</ArticleId><ArticleId IdType="pmc">PMC4391779</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0003692</ArticleId><ArticleId IdType="pii">PNTD-D-14-01608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, Chen YJ, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 1999;29: 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol. 2000;17: 23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Velez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA, Pallansch MA, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007;45: 950&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879907</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341: 936&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB, Lam SK. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999;61: 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10426204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, Hsu YT, et al. Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol. 2006;78: 254&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Huang SW, Lai YL, Lin CP, Shih CH, Huang CC, et al. On the relationship between the protein structure and protein dynamics. Proteins. 2008;72: 625&#x2013;634. 10.1002/prot.21954</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.21954</ArticleId><ArticleId IdType="pubmed">18247347</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick JL, Schmidt NJ, Mirkovic RR, Chumakov MP, Lavrova IK, Voroshilova MK. Identification of Bulgarian strain 258 of enterovirus 71. Intervirology. 1980;12: 297&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">6244233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71: 217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu TN, Tsai SF, Li SF, Lee TF, Huang TM, Wang ML, et al. Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis. 1999;5: 458&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640775</ArticleId><ArticleId IdType="pubmed">10341187</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19: 424&#x2013;429. 10.1038/nsmb.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15: 798&#x2013;801. 10.1038/nm.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15: 794&#x2013;797. 10.1038/nm.1961</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8: e57591 10.1371/journal.pone.0057591</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110: 14753&#x2013;14758. 10.1073/pnas.1217563110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, Chow YH, et al. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods. 2011;173: 189&#x2013;195. 10.1016/j.jviromet.2011.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.02.003</ArticleId><ArticleId IdType="pubmed">21315763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HW, Lin YW, Ho HM, Lin MH, Liu CC, Shao HY, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One. 2013;8: e69858 10.1371/journal.pone.0069858</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069858</ArticleId><ArticleId IdType="pmc">PMC3728341</ArticleId><ArticleId IdType="pubmed">23936115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Ih Jen S, et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine. 2012;30: 703&#x2013;711. 10.1016/j.vaccine.2011.11.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.087</ArticleId><ArticleId IdType="pubmed">22142585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al. Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLoS One. 2013;8: e79783 10.1371/journal.pone.0079783</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine. 2009;27: 5460&#x2013;5471. 10.1016/j.vaccine.2009.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.07.004</ArticleId><ArticleId IdType="pubmed">19622401</ArticleId></ArticleIdList></Reference><Reference><Citation>Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clinical and vaccine immunology: CVI. 2009;16: 1285&#x2013;1292. 10.1128/CVI.00144-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00144-09</ArticleId><ArticleId IdType="pmc">PMC2745015</ArticleId><ArticleId IdType="pubmed">19605598</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003;77: 10780&#x2013;10789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224991</ArticleId><ArticleId IdType="pubmed">14512528</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81: 6594&#x2013;6604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900096</ArticleId><ArticleId IdType="pubmed">17428852</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78: 7916&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, et al. A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SC, Liu CC, Lian WC. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004;22: 3858&#x2013;3864.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364432</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, et al. Human SCARB2-mediated entry and endocytosis of EV71. PLoS One. 2012;7: e30507 10.1371/journal.pone.0030507</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030507</ArticleId><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29: 4362&#x2013;4372. 10.1016/j.vaccine.2011.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998;9: 2577&#x2013;2583.</Citation><ArticleIdList><ArticleId IdType="pubmed">9853524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry. 1976;72: 248&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ MH. A simple method of estimating 50 percent end-points. Am J Hyg. 1938;27: 493&#x2013;497.</Citation></Reference><Reference><Citation>Fundamental Virology. Fourth Edition ed.: Lippincott Williams and Wilkins; 2001.</Citation></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6: e20005 10.1371/journal.pone.0020005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chow YH, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014 DOI: 10.1016/j.vaccine.2014.08.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.064</ArticleId><ArticleId IdType="pubmed">25218294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang KD, Yang MY, Li CC, Lin SF, Chong MC, Wang CL, et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis. 2001;183: 850&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatric research. 2006;60: 466&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010;9: 149&#x2013;156. 10.1586/erv.09.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and infection / Institut Pasteur. 2006;8: 1671&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24: 2944&#x2013;2951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125: 61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81: 3514&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866067</ArticleId><ArticleId IdType="pubmed">17251294</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir P, Kammerer U, Korn K, Mulders MN, Poyry T, Weissbrich B, et al. Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis. Clinical microbiology reviews. 1998;11: 202&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC121380</ArticleId><ArticleId IdType="pubmed">9457433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30: 1305&#x2013;1312. 10.1016/j.vaccine.2011.12.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology. 2007;363: 59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17320136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinkernagel RM. On natural and artificial vaccinations. Annual review of immunology. 2003;21: 515&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">12500980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunology and cell biology. 2004;82: 506&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">15479436</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine. 2009 DOI: S0264-410X(09)00992-X [pii] 10.1016/j.vaccine.2009.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.07.004</ArticleId><ArticleId IdType="pubmed">19622401</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Human gene therapy. 2005;16: 149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15761255</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183: 1485&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">11319684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109: e88</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291: 222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Deng C, Wan J, Zhu L, Leng Q. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8: 306 10.1186/1743-422X-8-306</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-306</ArticleId><ArticleId IdType="pmc">PMC3142239</ArticleId><ArticleId IdType="pubmed">21679417</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Chang IS, Chen WJ, Huang YC, Chen GW, Shih SR, et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008;122: 1271&#x2013;1276. 10.1542/peds.2007-3735</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2007-3735</ArticleId><ArticleId IdType="pubmed">19047245</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>